Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cholinergic Agents Clear all
Completed Phase 1 Interventional

Clinical Trial of AVL-3288 in Schizophrenia Patients

NCT02978599
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
AVL-3288, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 27, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion

NCT01951729
View directory record Official record
Conditions
Pre-diabetes
Interventions
Control, Xenin-25 without atropine, GIP without atropine, Placebo with atropine, Xenin-25 with atropine, GIP with atropine, GIP plus Xenin-25 without atropine, GIP plus Xenin-25 with atropine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Sep 27, 2026, 9:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Imaging in Elderly People and Individuals With Alzheimer's Disease

NCT00001917
View directory record Official record
Conditions
Alzheimer's Disease, Healthy
Interventions
O15, [F-18] FP-TZTP
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 27, 2026, 9:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Imaging in Depression

NCT00050700
View directory record Official record
Conditions
Depression, Bipolar Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 27, 2026, 9:32 AM EDT
Completed Not applicable Interventional Results available

Stimulation of Cingulo-opercular Alertness Network

NCT04817891
View directory record Official record
Conditions
Lewy Body Disease, Lewy Body Variant of Alzheimer Disease, Lewy Body Dementia With Behavioral Disturbance
Interventions
HD-tDCS
Device
Lead sponsor
University of Michigan
Other
Eligibility
50 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 27, 2026, 9:32 AM EDT
Completed Phase 4 Interventional

Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease

NCT03840837
View directory record Official record
Conditions
Parkinson Disease, Parkinson Disease Dementia
Interventions
Rivastigmine transdermal patch
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 27, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies

NCT00055575
View directory record Official record
Conditions
Mood Disorders, Healthy, Unipolar Depression, Bipolar Depression
Interventions
Scopolamine Nasal Spray
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced Sep 27, 2026, 9:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Executive, Activities of Daily Living, and Cholinergic Functions in Parkinson's Disease

NCT00737217
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Behavioral assessment/questionnaire
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 27, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using a Transcutaneous Electrical Auricular Stimulator to Harness the Cholinergic Anti-Inflammatory Pathway

NCT02910973
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vagus Nerve Stimulation, Sham Vagus Nerve Stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 27, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Results available

The Antidepressant Efficacy of the Anticholinergic Scopolamine

NCT00369915
View directory record Official record
Conditions
Unipolar Depression, Bipolar Depression
Interventions
Scopolamine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2016 · Synced Sep 27, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Results available

Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIA

NCT05710640
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
Active tcVNS, Sham tcVNS
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
San Francisco, California • Orlando, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 27, 2026, 9:32 AM EDT
Not yet recruiting Early Phase 1 Interventional

Human Cognition During Surgery: Stimulation-based and Cholinergic Modulation

NCT07721272
View directory record Official record
Conditions
Epilepsy, Essential Tremor, Seizures, Memory Consolidation, Memory Disorders, Memory Replay, Memory Encoding, Cognitive Control, Motor Abilities
Interventions
Cobenfy KarXT pill (50/20 mg), Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 27, 2026, 9:32 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
Remibrutinib, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 27, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Varenicline Treatment of Alcohol Dependence in Smokers

NCT01553136
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse, Smoking, Alcohol Drinking
Interventions
Varenicline
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
New Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Sep 27, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Nicotinic Cholinergic System and Cognitive Aging

NCT03408574
View directory record Official record
Conditions
Healthy Aging
Interventions
Nicotine patch, oral mecamylamine, placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 27, 2026, 9:32 AM EDT
Completed Not applicable Interventional Results available

A Study to Help People Quit Smoking.

NCT01880099
View directory record Official record
Conditions
Nicotine Dependence
Interventions
placebo, Galantamine 8mg, Galantamine 16mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 27, 2026, 9:32 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

NCT07122193
View directory record Official record
Conditions
Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors, Membrane Transport Modulators, Molecular Mechanisms of Pharmacological Action, Cholinergic Agents, Neurotransmitter Agents, incobotulinumtoxinA, Botulinum Toxins, Type A
Interventions
NT 201, NT 201 Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
27
States / cities
Scottsdale, Arizona • Encino, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 27, 2026, 9:32 AM EDT
Completed Phase 3 Interventional

Evaluation of Galantamine in the Treatment of Alzheimer's Disease

NCT00000172
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Galantamine
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
55
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 9:32 AM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines

NCT05024058
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
Ligelizumab, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Evansville, Indiana • North Charleston, South Carolina • El Paso, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 27, 2026, 9:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cholinergic Mechanisms of Attention in Aging

NCT04756232
View directory record Official record
Conditions
Subjective Cognitive Decline
Interventions
Mecamylamine Challenge, Placebo Comparator Challenge
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
55 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 27, 2026, 9:32 AM EDT
Completed No phase listed Observational

Decrease in Sense of Smell and Associated Cognitive Decline in Parkinson's Disease

NCT01572142
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Sep 27, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People With Inflammatory Arthritis

NCT06555562
View directory record Official record
Conditions
Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
Ultrasound Stimulation, Non-active ultrasound stimulation
Device
Lead sponsor
Surf Therapeutics
Industry
Eligibility
22 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Austin, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 27, 2026, 9:32 AM EDT
Not listed Phase 3 Interventional

Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome

NCT00069550
View directory record Official record
Conditions
Rett Syndrome
Interventions
dextromethorphan, donepezil hydrochloride
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Year to 15 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 9:32 AM EDT
Completed Not applicable Interventional Results available

Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain

NCT02822989
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Musculoskeletal Pain
Interventions
Vagus nerve stimulation, Sham vagus nerve stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 27, 2026, 9:32 AM EDT